子宫内膜异位症非激素类药物的研究进展  

Advances in Non-Hormonal Drugs of Endometriosis

作　　者：王英巧 李咏[1] 孔成才 WANG Ying-qiao;LI Yong;KONG Cheng-cai(Department of Gynecology,Changzhou Maternal and Child Health Hospital Affiliated to Nanjing Medical University,Changzhou 213000,Jiangsu Province,China)

机构地区：[1]南京医科大学附属常州市妇幼保健院妇科,江苏省常州市213000

出　　处：《国际妇产科学杂志》2021年第3期286-289,共4页Journal of International Obstetrics and Gynecology

基　　金：国家自然科学基金(81701516);江苏省卫生健康委重点B类项目(ZDB2020031)。

摘　　要：随着对子宫内膜异位症(endometriosis,EMs)发病机制研究逐渐深入,认识到EMs不只是激素依赖性疾病,炎症、免疫系统紊乱、氧化应激失调等也参与子宫内膜碎片在“异地”的黏附、侵袭和生长,这些微环境的异常为EMs的非激素类药物治疗提供了新的研究方向。介绍肿瘤坏死因子α(TNF-α)抑制剂、3-羟基-3甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂、大环内酯类药物、瘦素及瘦素受体拮抗剂、植物类药物等非激素类药物应用于EMs中的研究进展,帮助临床工作者了解非激素类药物治疗前景。With the development of the research on the pathogenesis of endometriosis(EMs),EMs is no longer a hormone-dependent disease,inflammation,immune dysfunction and oxidative stress disorder are also involved in the adhesion,invasion and growth of endometriosis fragments in"different places".These abnormalities in the endometrial microenvironment provide new research directions for the treatment of EMs with non-hormonal drugs.This review focuses on the research progress of non-hormonal drugs such as TNF-αinhibitors,HMG-CoA reductase inhibitors,macrolides,leptin and leptin receptor antagonist and plants,for clinical workers to better understand the therapeutic prospect of non-hormonal drugs.

关 键 词：子宫内膜异位症 羟甲基戊二酰基COA还原酶抑制剂 大环内酯类 姜黄素 非激素类药物 肿瘤坏死因子α抑制剂 抗瘦素信号 

分 类 号：R711.71[医药卫生—妇产科学]